Drug Trial Radar · NCT00002653
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 1993
Primary completion
Not stated
Sponsor
- Lead sponsor
- Medical Research CouncilGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Apr 10, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating older patients with multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without cyclophosphamide and prednisone in treating older patients with multiple myeloma.
Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustineDrug
cyclophosphamideDrug
doxorubicin hydrochlorideDrug
melphalanDrug
prednisoneDrug
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MRC Myelomatosis Trials Office
Birmingham, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.